What is CovalX?
CovalX stands as a premier provider of advanced solutions for the characterization of therapeutic proteins. The company specializes in intricate epitope mapping and detailed protein interaction analysis, leveraging a comprehensive suite of mass spectrometry techniques. These include cutting-edge methods such as XL-MS, HDX-MS, and mAb characterization, all designed to empower clients within the pharmaceutical and biotechnology industries. CovalX's mission is to accelerate scientific discovery and facilitate breakthroughs that advance human health, serving a global clientele of notable organizations.
How much funding has CovalX raised?
CovalX has raised a total of $89K across 1 funding round:
Debt
$89K
Debt (2021): $89K with participation from PPP
Key Investors in CovalX
PPP
Public-Private Partnership
What's next for CovalX?
With the infusion of substantial expansion capital, CovalX is strategically positioned for accelerated growth and enhanced market penetration. This significant Series B/C stage investment will likely fuel further development of their innovative protein characterization technologies and expand their service offerings. The company's focus on supporting critical research in the life sciences suggests a future emphasis on deepening partnerships with pharmaceutical and biotech firms, potentially leading to new therapeutic developments and diagnostic tools. CovalX's commitment to quality and scientific advancement indicates a continued drive towards solidifying its leadership in the protein analysis market.
See full CovalX company page
